Sugi Predict
/ Targets
/ ATM
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to ATM by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) |
PHASE4 | UNKNOWN |
| Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone |
PHASE4 | COMPLETED |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers |
PHASE1/PHASE2 | NOT_YET_RECRUITING |
| Effects of Vitamin B3 in Patients With Ataxia Telangiectasia |
PHASE2 | COMPLETED |
| Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma |
PHASE1/PHASE2 | COMPLETED |
| Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations |
PHASE2 | COMPLETED |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors |
PHASE1/PHASE2 | RECRUITING |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment. |
PHASE2 | WITHDRAWN |
| Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects |
PHASE1/PHASE2 | COMPLETED |
| A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer |
PHASE2 | COMPLETED |
| This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO) |
PHASE2 | UNKNOWN |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors |
PHASE1 | RECRUITING |
| Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma |
PHASE1 | RECRUITING |
| First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer |
PHASE1 | RECRUITING |
| M6620 Plus Standard Treatment in Oesophageal and Other Cancer |
PHASE1 | COMPLETED |
| Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer |
PHASE1 | WITHDRAWN |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients |
PHASE1 | COMPLETED |
| Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein |
nan | COMPLETED |
| Whole Body MRI for Cancer Surveillance in A-T |
nan | COMPLETED |
| A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia |
nan | UNKNOWN |
| Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors |
nan | UNKNOWN |
| Genetics of Prostate Cancer in Young Patients |
nan | COMPLETED |
| Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside |
nan | UNKNOWN |
| Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy |
nan | WITHDRAWN |
| Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a ATM binder may also engage these)